PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic® M (for acute relief of migraine headaches), LipiGesic® H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
The second, longer term, opportunity is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a “new kind of product line.” Our product line will consist of ‘alternative’ remedies for common ailments, marketed to the masses. Most consumers want products that are, first of all, effective and safe. By applying hard science to ‘natural’ products, management believes it is possible to build a line wherein each product delivers better performance with fewer side effects than its chemical counterparts. With effective marketing, these products will be embraced by the majority, many of whom prefer ‘natural’ alternatives, provided there is no need to sacrifice performance or convenience.
PuraMed BioScience has completed a double blind placebo clinical trial for its leading product, LipiGesic® M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract LipiGesic® M has national distribution and is available nationwide in some of the largest chain drug stores in the United States.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.